tbuckley/cabot-search huggingface dataset:
TOBACCO AND ARTERIOSCLEROSIS.
Authors: F Martorell
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BMA annual meeting: Doctors’ leader attacks government for “wasted year” on seven day NHS
Authors: Zosia Kmietowicz
Journal: BMJ (2016)

The leader of doctors in the United Kingdom has accused the government of “a wasted year” in which it pursued its policy of a seven day NHS in a vacuum of evidence rather than dealing with the financial crisis in the health service.

Speaking at the BMA’s annual representatives meeting in Belfast on 20 June, Mark Porter said that the line in the Conservatives’ 2015 election manifesto to deliver “a truly seven day NHS” had led to a “needless dispute with [the medical] profession.”

He told representatives, “[The policy] will mystify those who look back and ask what kind …
Dr. Goldberg replies (American Journal of Psychiatry (February 2008) 165 (264))
Authors: Roy H. Perlis, S. Nassir Ghaemi, Joseph R. Calabrese, Charles L. Bowden, Stephen R. Wisniewski, David J. Miklowitz, Gary S. Sachs, Michael E. Thase
Journal: American Journal of Psychiatry (2008)
How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).
Authors: Fabienne McClanahan, Thomas Hielscher, Michael Rieger, Manfred Hensel, Martin Bentz, Ingo Schmidt-Wolf, Andreas Kaebisch, Hans-Jürgen Salwender, Heinz Dürk, Hans Juergen Staiger, Thomas Mandel, Kai Neben, Jens Hillengass, Anthony D. Ho, Mathias Witzens-Harig
Journal: Blood (2009)
Cancer Investigators Make Strides in Improving Patients’ Quality of Life
Authors: Tracy Hampton
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Programmed Nanoparticles for Tailoring the Detection of Inflammatory Bowel Diseases and Irritable Bowel Syndrome Disease via Breathprint
Authors: Amir Karban, Morad K. Nakhleh, John C. Cancilla, Rotem Vishinkin, Tova Rainis, Eduard Koifman, Raneen Jeries, Hodaya Ivgi, Jose S. Torrecilla, Hossam Haick
Journal: Advanced Healthcare Materials (2016)

Chemical sensors based on programmable molecularly modified gold nanoparticles are tailored for the detection and discrimination between the breathprint of irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). The sensors are examined in both lab- and real-world clinical conditions. The results reveal a discriminative power accuracy of 81% between IBD and IBS and 75% between Crohn's and Colitis states.
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas
Authors: M. A. Vogelbaum, B. Berkey, D. Peereboom, C. Giannini, J. Suh, P. Brown, D. Blumenthal, C. Biggs, C. Schultz, M. Mehta
Journal: Journal of Clinical Oncology (2005)

1520 Background: RTOG 9402 showed that a dose-intense pre-radiation chemotherapy regimen consisting of procarbazine, lomustine and vincristine (PCV) for anaplastic oligodendrogliomas (AOs) and mixed anaplastic oligoastrocytomas (MAOs) produced improved progression free survival at the expense of increased toxicity, but no improvement in overall survival. A less toxic chemotherapy, temozolomide (TMZ), has also shown efficacy in several glial tumors, and it can be given concurrently with radiation therapy (RT) with acceptable toxicity. Methods: A phase II study was performed to evaluate the efficacy of pre-RT TMZ and the toxicity of concurrent RT and TMZ in patients with newly diagnosed AO or MAO. The primary endpoint was to determine the pre-RT TMZ six-month progression rate. Results: 40 eligible patients were entered into the trial; 55% were male, median age was 45, 50% had an AO. Twenty-seven patients completed 6 months of pre-RT TMZ and have undergone central review, and three are too early to evaluate. Of the remaining ten patients, two withdrew early due to tumor progression (not reviewed) and 4 withdrew due to toxicity. Four other patients withdrew from study without evidence of toxicity or progression. Pre-RT TMZ responses in centrally-reviewed patients (N = 27) were as follows: 1 CR (3.7%), 8 PR (29.6%), 15 SD (55.6%) and 1 PD (3.7%). CR required resolution of both T1 and T2 changes. Two patients (7.4%) had no evaluable disease. If the 2 patients who withdrew due to reported progression are included, the 6-month progression rate is 3/29 (10.3%). During concurrent RT and TMZ treatment there were two (5%) grade 3 and zero grade 4 non-hematologic toxicities. Conclusions: Pre-RT TMZ appears to be feasible, without an inordinately high rate of early progression (10.3%). In comparison, the overall 6-month progression rate observed in the pre-RT PCV arm of RTOG 9402 was 20%. Toxicity of the concurrent RT and TMZ regimen was acceptable. Analysis of tumor 1p/19q status is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering Oncology
Estimating Glomerular Filtration Rate
Authors: Marc G Vervloet, Yvo M Smulders
Journal: New England Journal of Medicine (2012)

Almost all laboratories in The Netherlands report an estimated glomerular filtration rate (eGFR) whenever a value for plasma creatinine is requested. This formula is based on gender and age, besides the plasma creatinine concentration, and sometimes also a correction for race is applied. While this GFR reporting improved the recognition of chronic kidney disease, the formulas used have intrinsic limitations. Moreover, recently a novel formula that obviates the need for a correction factor for race has been proposed. In this article the strengths and weaknesses of plasma creatinine and formulas based on that are discussed, following ten frequently asked questions.
Treatment for intestinal helminth infection
Authors: E Michael, A Bhargava, D Bundy, R Peto, E Cooper, L Savioli, M Neira, M Albonico, M J Beach, H M Chwaya, Crompton Dwt., J Dunne, J P Ehrenberg, T Gyorkos, J Kvalsvig, M G Taylor, C Urbani, F Zheng, P Garner, R Dickson, C Demellweek, P Williamson, S Awasthi
Journal: BMJ (2000)
Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).
Authors: Martin Reck, Luis G. Paz-Ares, Paolo Bidoli, Federico Cappuzzo, Shaker R. Dakhil, Denis Moro-Sibilot, Hossein Borghaei, Melissa Lynne Johnson, Robert M. Jotte, Nathan A. Pennell, Frances A. Shepherd, Anne S. Tsao, Gebra Cuyun Carter, Faye Diehl, Ekaterine Alexandris, Pablo Lee, Annamaria Zimmermann, Joseph Treat, Andreas Sashegyi, Maurice Perol
Journal: Journal of Clinical Oncology (2016)

9079 Background: REVEL demonstrated that the addition of RAM to DOC in the 2L treatment of pts with advanced NSCLC led to a consistent improvement in OS, PFS, and ORR, independent of histology. Pts refractory to 1L therapy (best response of progressive disease) have a particularly poor prognosis and represent a challenging subgroup of pts to treat. We report relevant outcomes in refractory pts who participated in the REVEL trial. Methods: Pts with advanced NSCLC of squamous or nonsquamous histology with disease progression during or after 1L platinum-based chemotherapy were randomized (1:1) to receive DOC 75 mg/m2and either RAM 10 mg/kg or PBO on day 1 of a 21-day cycle. OS was the primary endpoint. Secondary endpoints included PFS, ORR, safety, and patient-reported quality-of-life. Response was assessed according to RECIST v1.1. Results: Of 1,253 pts in REVEL, 29% were refractory. In the control arm, median OS among refractory pts was 6.3 mos v 10.3 mos for pts not meeting this criterion, demonstrating the poor prognosis of refractory pts. Baseline characteristics of the refractory subgroup were balanced between treatment arms. Conclusions: The effect of RAM+DOC for treating pts with advanced NSCLC refractory to 1L therapy appears consistent with the intent-to-treat population. The benefit/risk profile for refractory pts suggests that RAM+DOC is an appropriate treatment option even in this difficult-to-treat population. Clinical trial information: NCT01168973.REVEL Refractory Pts. RAM+DOC n=178 PBO+DOC n=182 HR (95% CI) Baseline characteristics, n (%) Age, median (range) 63 (23-84) 60 (29-87) Male 137 (77) 127 (70) ECOG PS 0 53 (30) 50 (27) 1 125 (70) 132 (73) Time since prior therapy <9 mos 156 (88) 154 (85) Histology Nonsquamous 130 (73) 130 (71) Squamous 46 (26) 50 (27) Outcomes Median OS, mos 8.3 6.3 0.86 (0.68, 1.08) Median PFS, mos 4.0 2.5 0.71 (0.57, 0.88) ORR 23% 13% Total LCSS score, time to deterioration 0.77 (0.51, 1.17) TEAEs, n (%) Any TEAE 173 (97) 171 (95) Gr ≥3 TEAEs 131 (74) 126 (70) Serious TEAEs 80 (45) 84 (47) TEAEs leading to discontinuation 9 (5) 7 (4) TEAEs leading to death 11 (6) 17 (9)
Patient satisfaction with doctor and nurse communication varies with patient education level, age, gender, and primary language.
Authors: Daniel Curtis McFarland, Randall F. Holcombe
Journal: Journal of Clinical Oncology (2014)

198 Background: Hospital Consumer Assessments of Healthcare Providers and Systems (HCAHPS) surveys are used to enhance quality care. Non-random patient satisfaction variance is evident from HCAHPS scores which could be due to varying perception of quality care across demographically heterogeneous areas of the USA. Methods: HCAHPS, hospital bed, and county demographic data were obtained from the Hospital Compare, American Hospital Directory, and US Census Bureau websites, respectively. Multivariate regression modeling was performed for all ten dimensions of HCAHPS scores. Standardized partial regression coefficients were used to assess strengths of predictors (Table). Results: HCAHPS scores were obtained from 3,192 hospitals and demographic data collected from all 3,144 county or county equivalents. While most predictors were significant, ‘bachelor’s degree’ most strongly predicted for favorable satisfaction for MD communication and ‘white alone percent’ most strongly predicted favorable satisfaction for RN communication. Age (over 65), non-English speaking, female, average household size and high school education predicted worse satisfaction with both MD and RN communication. Conclusions: In conclusion, a communication quality gap exists for less educated, non-white, elderly, non-English speaking and female sections of the population. Research should focus on enhancing delivery of quality communication for these subpopulations. [Table: see text]
European Perspectives
Authors: Ian Macdonald
Journal: Circulation (2007)

and is a member of the Hellenic Cardiology Society.Perhaps it is not surprising that she has chosen cardiology as her career path because it follows a deep-seated love of medicine and cardiology in her family, and she is well-known for her work."I was inspired by my family," she says."I come from four generations of doctors."Her maternal grandfather studied in Paris and was a gynaecologist; her paternal grandfather studied internal medicine in Italy.Her father was a cardiologist, and she describes how her maternal grandfather in particular had a respect for human life."Many times he offered his services for free," she says.Dr Chrysohoou's decision to pursue cardiology stems from a love of both clinical work-"being close to the patient"-and being able to use the newer developing procedures such as echocardiography, magnetic resonance imaging, and catheterisation."In cardiology, you have to examine your patients and talk to them every day, whereas in internal medicine, you talk to the patient, but you don't have the interesting procedures."She also appreciates how cardiology is more centred on a single system in the body.She began her studies in 1986 at the age of 18, at Patras University Medical School.Her first job, from 1993 to 1994, was as a general physician in small villages in Greece, upholding the country's tradition of graduates doing this type of work for the state for 1 year.Dr Chrysohoou then studied internal medicine for a year, in 1994, at St Anargyroi Oncological Hospital in Athens.From 1995 to 2000, she pursued her studies in cardiology at First Cardiology Clinic, and began a PhD programme in 2002, during which she looked at echocardiographic evaluation of left ventricular systolic function in patients with coronary heart disease in comparison with apex cardiography.For the past 4 years, Dr Chrysohoou has specialised in heart failure.This has involved her in treating young patients with beta thalassaemia major (of which there are just 200 in Athens) and using echocardiography for coronary heart disease."I was really interested in heart failure because the number of patients with heart failure is increasing.Because of secondary prevention and invasive methods, we increase life expectancy, but heart failure is the final stage of disease."Outside of her family, her mentors included Steve Singh, MD, with whom she did a postdoctoral fellow-ship from 2004 to 2005 at the cardiology department of the Veterans Affairs Medical Center in Washington, DC, where he is head of the department."I liked the way he came close to the patient during the examination, and the way he interpreted the results and came Cardiology is a challenging profession, perhaps especially for women in Greece, who may have to overcome predjudice and juggle career and family.Dr Christina Chrysohoou talks to Jennifer Taylor about her life and career to date.
Studies on the Blood Supply of Tumors in Man. I. Fluorescence of Cutaneous Lesions&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Howard R. Bierman, Keith H. Kelly, Kenneth S. Dod, Ralph L. Byron, Jr.
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Studies on the Blood Supply of Tumors in Man. I. Fluorescence of Cutaneous Lesions Get access Howard R. Bierman, Howard R. Bierman Search for other works by this author on: Oxford Academic PubMed Google Scholar Keith H. Kelly, Keith H. Kelly Search for other works by this author on: Oxford Academic PubMed Google Scholar Kenneth S. Dod, Kenneth S. Dod Search for other works by this author on: Oxford Academic PubMed Google Scholar Ralph L. Byron, Jr. Ralph L. Byron, Jr. Laboratory of Experimental Oncology, National Cancer Institute, National Institutes of Health, U. S. Public Health Service, and the Division of Medicine and the Cancer Research Institute, University of California School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 5, April 1951, Pages 877–889, https://doi.org/10.1093/jnci/11.5.877 Published: 01 April 1951 Article history Received: 29 August 1950 Published: 01 April 1951
Gain(1)(q21) Defines Group of Newly Diagnosed Multiple Myeloma Patients with Poor Prognosis.
Authors: Pavel Nemec, Henrieta Greslikova, Romana Zaoralova, Jan Smetana, Hana Filkova, Elena Dementyeva, Renata Kupska, Kristina Berankova, Aneta Mikulasova, Ludek Pour, Lenka Zahradova, Petr Kuglik, Roman Hajek
Journal: Blood (2009)
NIMG-35RESULTS OF EXPLORATORY 18F-FLT PET IMAGING IN TEN RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH THE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER MIBEFRADIL FOLLOWED BY TEMOZOLOMIDE (ABTC TRIAL 1101)
Authors: Matthias Holdhoff, Martin A. Lodge, Asim K. Bag, L. Burt Nabors, Akiva Mintz, Glenn J. Lesser, David A. Mankoff, Arati S. Desai, Frank S. Lieberman, Jeffrey Leal, Joy D. Fisher, Serena Desideri, Xiaobu Ye, Stuart A. Grossman, David Schiff, Richard L. Wahl
Journal: Neuro-Oncology (2015)

BACKGROUND: Mibefradil (MIB) is a selective T-type calcium channel blocker that has shown preclinical impact on cell cycle activity, specificallyOverall survival
Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)
Authors: Ciara Louise Freeman, Franck Morschhauser, Laurie H. Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Gunter Fingerle-Rowson, Elisabeth Wassner-Fritsch, Michael Hallek, Gilles Salles, Guillaume Cartron
Journal: Blood (2014)
Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)
Authors: S. Delaloge, K. L. Tedesco, J. Blum, A. Gonçalves, J. Lubinski, N. Efrat, C. Osborne, C. Lebedinsky, J. C. Tercero, F. A. Holmes
Journal: Journal of Clinical Oncology (2009)

1010 Background: Trabectedin ([T]; Yondelis) binds to the minor groove of DNA; its cytotoxicity is determined by the synergistic action of two DNA repair mechanisms, the efficient nucleotide excision repair (NER) and deficient homologous recombination repair (HRR) machinery. T has EMEA authorization in soft tissue sarcoma after failure of standard treatment. Preliminary data have shown activity of T as single agent in MBC. Clinical and preclinical data suggested T may display specific activity among certain NER-intact or HRR-deficient MBC, and prompted this phase II trial dedicated to 3 subgroups: triple-negative (TN), HER-2-overexpressed, and BRCA1/2 germline-mutated MBC. Methods: T was given at 1.3 mg/m 2 as a 3- hour iv infusion every 3 weeks to pts with pretreated progressive MBC: Group A: TN; Group B: HER-2+++; Group C: BRCA1/2 mutation carriers. Endpoints were objective response (OR) rate by RECIST, duration of response, progression free survival (PFS), tumor volume changes, safety and exploratory pharmacogenomics (PGx). Results: A total of 95 women (median [med] age 52, ECOG 0/1 48/52%) have been enrolled (A:50, B:24, C:21) with data available for 72 pts. Med number of prior chemotherapy regimens: 4 (1–10). Med number of T cycles administered: 2 (1–12) for all groups. The most commonly reported grade 3/4 AEs are neutropenia (29/21%), ALT (28/2%) and AST (13/0). Alopecia/stomatitis, only G1, was reported in &lt;2% each. Long-lasting disease stabilizations were described in all groups. While OR were rare among TN MBC pts (2PR/43 evaluable), preliminary analysis by investigator shows efficacy in group C (4PR/11 evaluable). Tissue samples from 36 pts were collected for RNA expression analysis (XPG + ERCC1 + BRCA1). Preliminary results show high XPG is associated with longer PFS: 4.1 months (95% CI 2.6-not reached) versus 1.3 months (95% CI 1.2–3.7), p = 0.01. Analyses are ongoing. Conclusions: Trabectedin shows a manageable safety profile in the 3 groups of MBC with promising efficacy in certain DNA-repair machinery sub-categories defined molecularly. TN group was closed due to low response. More mature PGx results will be discussed to help selecting the patients who are at highest chance for response. [Table: see text]
Open trial of S-adenosylmethionine for treatment of depression
Authors: J F Lipinski, B M Cohen, F Frankenburg, M Tohen, C Waternaux, R Altesman, B Jones, P Harris
Journal: American Journal of Psychiatry (1984)

Nine depressed inpatients completed trials with S-adenosylmethionine. Seven showed improvement or remission of their symptoms. As in European studies, no side effects were seen except the apparent induction of mania in two patients with bipolar disorder.